Acute kidney injury after primary angioplasty: Effect of different hydration treatments

Journal of Cardiovascular Medicine

Volumn 15, Issue 1, 2014, Pages 60-67

  Manari, Antonio ^a   Magnavacchi, Paolo ^b   Puggioni, Enrico ^c   Vignali, Luigi ^d   Fiaccadori, Enrico ^e   Menozzi, Mila ^a   Tondi, Stefano ^b   Robotti, Stefano ^c   Ferrari, Duilio ^f   Valgimigli, Marco ^g  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b Nuovo Ospedale S Agostino   (Italy)

^c DEPARTMENT OF CARDIOLOGY   (Italy)

^d MAGGIORE HOSPITAL   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

^f IBIS Informatica   (Italy)

^g UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

acute kidney injury; acute myocardial infarction; angioplasty

Indexed keywords

BICARBONATE; CONTRAST MEDIUM; CREATININE; SODIUM CHLORIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CREATININE BLOOD LEVEL; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE KIDNEY INJURY; AGED; CONTRAST MEDIA; FEMALE; FLUID THERAPY; HUMANS; INCIDENCE; INFUSIONS, PARENTERAL; ITALY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RISK FACTORS; SODIUM BICARBONATE; SODIUM CHLORIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84894135145     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283641bb8     Document Type: Article

References (36)

1. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29:2909-2945.
2. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259-2264.
3. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51:1419-1428.
4. Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Interven Radiol 2005; 28:S3-S11.
5. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int 2006; 100:S11-S15.
6. Brown JR, DeVries JT, Robb JF, et al. Serious renal dysfunction after percutaneous coronary intervention can be predicted. Am Heart J 2008; 155:260-266.
7. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004; 44:1780-1785.
8. Wickenbrock I, Perings C, Maagh P, et al. Contrast induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome: differences in STEMI and NSTEMI. Clin Res Cardiol 2009; 89:765-772.
9. McCullough PA, Wolyn R, Rocher R, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103:368-375.
10. Best PJM, Lennon R, Ting HH, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39:1113-1119.
11. Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during percutaneous intervention and subsequent contrast-induced nephropathy and mortality. Ann Inter Med 2009; 150:170-177.
12. McCollough PA, Adam A, Becker CR, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006; 98 (6A):5K-13K
13. James MT, Ghali WA, Knudtson Ml, et al., for the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 2011; 123:409-416.
14. Pyraxas SA, Sinagra G, Mangiacapra F, et al. Contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention without acute left ventricular ejection fraction impairment. Am J Cardiol 2013; 111:684-688.
15. Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int 2006; 69:S51-S53.
16. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate. JAMA 2004; 291:2328-2334.
17. Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrastinduced nephropathy in primary angioplasty. N Engl J Med 2006; 354:2773-2782.
18. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose Nacetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2010; 55:2201-2209.
19. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med 1989; 86:649-652.
20. Laskey WK, Jenkins C, Selzer F, et al., NHLBI Dynamic Registry Investigators. Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. J Am Coll Cardiol 2007; 50:584-590.
21. Recio-Mayoral A, Chaparro M, Prado B, et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 2007; 49:1283-1288.
22. Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 2007; 100:781-786.
23. William W, Kolh P, Danchin N, et al., Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31:2501-2555.
24. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002; 137:563-570.
25. Goldberg A, Hammerman H, Petcherski S, et al. In hospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J 2005; 150:330-337.
26. Romano G, Briguori C, Quintavalle C, et al. Contrast agents and renal cell apoptosis. Eur Heart J 2008; 29:2569-2576.
27. Stacul F, Adam A, Becker CR, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006; 98 (6A):59K-77K.
28. Zoungas S, Ninomiya T, Huxley R, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 2009; 151:631-638.
29. Kunadian V, Zaman A, Spyridopoulos I, Qiu W. Sodium bicarbonate for the prevention of contrast induced nephropathy: a meta-analysis of published clinical trials. Eur J Radiol 2011; 79:48-55.
30. Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int 2006; 69:S8-S10.
31. Ueda H, Yamada T, Masuda M, et al. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures. Am J Cardiol 2011; 107:1163-1167.
32. Leone AM, De Caterina AR, Sciahbasi A, et al. Sodium bicarbonate plus Nacetylcysteine to prevent contrast-induced nephropathy in primary and rescue percutaneous coronary interventions: the BINARIO (Bicarbonato e N-Acetil-cisteina nell'infaRto mIocardico acutO) study. EuroIntervention 2012; 8:839-847.
33. Mager A, Assa HV, Lev EI, et al. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction. Cath Cardiov Intev 2011; 78:198-201.
34. Brown JR, Robb JF, Block CA, et al. Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury? Circ Cardiovasc Interv 2010; 3:346-350.
35. Valgimigli M, Campo G, Percoco G, et al. Comparison of angioplasty with infusion of tirofiban orabciximab and with implantation of sirolimus-eluting or uncoated stents for Acute Myocardial Infarction The MULTISTRATEGY Randomized Trial. JAMA 2008; 299:1788-1799.
36. Marzocchi A, Manari A, Piovaccari G, et al., on behalf of the FATA Investigators. Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty: results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trial. Eur Heart J 2008; 29:2972-2980.